Literature DB >> 26598923

Effect of hypoxia on tissue factor pathway inhibitor expression in breast cancer.

X Y Cui1,2,3,4, M Tinholt1,3,4,5, B Stavik1,3, A E A Dahm2,4,6, S Kanse1,3,7, Y Jin8, S Seidl1,3,7, K K Sahlberg9,10,11, N Iversen5, G Skretting1,3, P M Sandset1,3,4.   

Abstract

UNLABELLED: ESSENTIALS: A hypoxic microenvironment is a common feature of tumors that may influence activation of coagulation. MCF-7 and SK-BR-3 breast cancer cells and breast cancer tissue samples were used. The results showed transcriptional repression of tissue factor pathway inhibitor expression in hypoxia. Hypoxia-inducible factor 1α may be a target for the therapy of cancer-related coagulation and thrombosis.
BACKGROUND: Activation of coagulation is a common finding in patients with cancer, and is associated with an increased risk of venous thrombosis. As a hypoxic microenvironment is a common feature of solid tumors, we investigated the role of hypoxia in the regulation of tissue factor (TF) pathway inhibitor (TFPI) expression in breast cancer.
OBJECTIVES: To explore the transcriptional regulation of TFPI by hypoxia-inducible factor (HIF)-1α in breast cancer cells and their correlation in breast cancer tissues. METHODS AND
RESULTS: MCF-7 and SK-BR-3 breast cancer cells were cultured in 1% oxygen or treated with cobalt chloride (CoCl2 ) to mimic hypoxia. Time-dependent and dose-dependent downregulation of TFPI mRNA (quantitative RT-PCR) and of free TFPI protein (ELISA) were observed in hypoxia. Western blotting showed parallel increases in the levels of HIF-1α protein and TF. HIF-1α inhibitor abolished or attenuated the hypoxia-induced downregulation of TFPI. Luciferase reporter assay showed that both hypoxia and HIF-1α overexpression caused strong repression of TFPI promoter activity. Subsequent chromatin immunoprecipitation and mutagenesis analysis demonstrated a functional hypoxia response element within the TFPI promoter, located at -1065 to -1060 relative to the transcriptional start point. In breast cancer tissue samples, gene expression analyses showed a positive correlation between the mRNA expression of TFPI and that of HIF-1α.
CONCLUSIONS: This study demonstrates that HIF-1α is involved in the transcriptional regulation of the TFPI gene, and suggests that a hypoxic microenvironment inside a breast tumor may induce a procoagulant state in breast cancer patients.
© 2015 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  HIF-1α protein; blood coagulation; breast cancer; human; hypoxia; tissue factor pathway inhibitor

Mesh:

Substances:

Year:  2016        PMID: 26598923     DOI: 10.1111/jth.13206

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  9 in total

Review 1.  Hypoxia-dependent signaling in perioperative and critical care medicine.

Authors:  Kiichi Hirota
Journal:  J Anesth       Date:  2021-05-18       Impact factor: 2.078

Review 2.  Potential Coagulation Factor-Driven Pro-Inflammatory Responses in Ovarian Cancer Tissues Associated with Insufficient O₂ and Plasma Supply.

Authors:  Shiro Koizume; Yohei Miyagi
Journal:  Int J Mol Sci       Date:  2017-04-12       Impact factor: 5.923

Review 3.  Development of Inhibitors Targeting Hypoxia-Inducible Factor 1 and 2 for Cancer Therapy.

Authors:  Tianchi Yu; Bo Tang; Xueying Sun
Journal:  Yonsei Med J       Date:  2017-05       Impact factor: 2.759

Review 4.  Hypoxia-Inducible Factors as an Alternative Source of Treatment Strategy for Cancer.

Authors:  Musbau Adewumi Akanji; Damilare Rotimi; Oluyomi Stephen Adeyemi
Journal:  Oxid Med Cell Longev       Date:  2019-08-14       Impact factor: 6.543

5.  Hypoxia inhibits TNF-α-induced TSLP expression in keratinocytes.

Authors:  Naoyuki Tashiro; Ryosuke Segawa; Ryozo Tobita; Sanki Asakawa; Natsumi Mizuno; Masahiro Hiratsuka; Noriyasu Hirasawa
Journal:  PLoS One       Date:  2019-11-04       Impact factor: 3.240

6.  Tissue factor pathway inhibitor upregulates CXCR7 expression and enhances CXCL12-mediated migration in chronic lymphocytic leukemia.

Authors:  Xue Yan Cui; Geir Erland Tjønnfjord; Sandip M Kanse; Anders Erik Astrup Dahm; Nina Iversen; Christiane Filion Myklebust; Ling Sun; Zhong Xing Jiang; Thor Ueland; James J Campbell; Mitchell Ho; Per Morten Sandset
Journal:  Sci Rep       Date:  2021-03-04       Impact factor: 4.379

7.  Design of a synthesis-friendly hypoxia-responsive promoter for cell-based therapeutics.

Authors:  Chee Ka Candice Lam; Kevin Truong
Journal:  Eng Life Sci       Date:  2021-10-29       Impact factor: 2.678

8.  Oridonin inhibits VEGF-A-associated angiogenesis and epithelial-mesenchymal transition of breast cancer in vitro and in vivo.

Authors:  Chunyu Li; Qi Wang; Shen Shen; Xiaolu Wei; Guoxia Li
Journal:  Oncol Lett       Date:  2018-06-11       Impact factor: 2.967

Review 9.  Role of hypoxia in cancer therapy by regulating the tumor microenvironment.

Authors:  Xinming Jing; Fengming Yang; Chuchu Shao; Ke Wei; Mengyan Xie; Hua Shen; Yongqian Shu
Journal:  Mol Cancer       Date:  2019-11-11       Impact factor: 27.401

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.